Serum Protein Adsorption Modulates the Toxicity of Highly Positively Charged Hydrogel Surfaces
Source abstract
Abstract
Hydrogels formed from peptide self-assembly are a class of materials that are being explored for their utility in tissue engineering, drug and cell delivery, two- and three-dimensional cell culture, and as adjuvants in surgical procedures. Most self-assembled peptide gels can be syringe-injected in vivo to facilitate the local delivery of payloads, including cells, directly to the targeted tissue. Herein, we report that highly positively charged peptide gels are inherently toxic to cells, which would seem to limit their utility. However, adding media containing fetal bovine serum, a common culture supplement, directly transforms these toxic gels into cytocompatible materials capable of sustaining cell viability even in the absence of added nutrients. Multistage mass spectrometry showed that at least 40 serum proteins can absorb to a gel's surface through electrostatic attraction ameliorating its toxicity. Further, cell-based studies employing model gels having only bovine serum albumin, fetuin-A, or vitronectin absorbed to the gel surface showed that single protein additives can also be effective depending on the identity of the cell line. Separate studies employing these model gels showed that the mechanism(s) responsible for mitigating apoptosis involve both the pacification of gel surface charge and adsorbed protein-mediated cell signaling events that activate both the PI3/Akt and MAPK/ERK pathways which are known to facilitate resistance to stress-induced apoptosis and overall cell survival.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Supramolecular Self-Assembly in Materials · RNA Interference and Gene Delivery · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland 21702, United States
Funding
National Cancer Institute
References (49)
Show source-provided references
1. 10.1016/j.biomaterials.2005.01.02910.1016/j.biomaterials.2005.01.029 ↗
2. 10.1016/j.biomaterials.2008.07.00910.1016/j.biomaterials.2008.07.009 ↗
3. 10.1073/pnas.070198010410.1073/pnas.0701980104 ↗
4. 10.1016/j.biomaterials.2012.06.09710.1016/j.biomaterials.2012.06.097 ↗
5. 10.1021/ja076300z10.1021/ja076300z ↗
6. 10.1021/bm900113z10.1021/bm900113z ↗
7. 10.1016/j.biomaterials.2011.05.05210.1016/j.biomaterials.2011.05.052 ↗
8. 10.1016/j.biomaterials.2012.08.04610.1016/j.biomaterials.2012.08.046 ↗
9. 10.1021/acs.macromol.7b0105610.1021/acs.macromol.7b01056 ↗
10. 10.1002/ange.20180398310.1002/ange.201803983 ↗
11. 10.1021/acsami.9b1215210.1021/acsami.9b12152 ↗
12. 10.1002/adhm.20140006510.1002/adhm.201400065 ↗
13. 10.1039/c7ra12503h10.1039/c7ra12503h ↗
14. 10.1002/mabi.20180024910.1002/mabi.201800249 ↗
15. 10.1021/bm500075r10.1021/bm500075r ↗
16. 10.1039/c0sm00974a10.1039/c0sm00974a ↗
17. 10.1039/c5sm02902c10.1039/c5sm02902c ↗
18. 10.1002/mabi.20110023010.1002/mabi.201100230 ↗
19. 10.1021/acsami.5b1147310.1021/acsami.5b11473 ↗
20. 10.1002/psc.266610.1002/psc.2666 ↗
21. 10.1016/j.actbio.2009.07.03110.1016/j.actbio.2009.07.031 ↗
22. 10.1021/acs.biochem.8b0012510.1021/acs.biochem.8b00125 ↗
23. 10.1016/j.biomaterials.2009.01.01010.1016/j.biomaterials.2009.01.010 ↗
24. 10.1002/adma.20050152210.1002/adma.200501522 ↗
25. 10.1371/journal.pone.000011910.1371/journal.pone.0000119 ↗
26. 10.1016/j.actbio.2012.09.01010.1016/j.actbio.2012.09.010 ↗
27. 10.1039/c8sm02573h10.1039/c8sm02573h ↗
28. 10.1166/jbn.2016.213410.1166/jbn.2016.2134 ↗
29. 10.1021/ja027993g10.1021/ja027993g ↗
30. 10.1073/pnas.150931311210.1073/pnas.1509313112 ↗
31. 10.1021/la204174610.1021/la2041746 ↗
32. 10.1039/b717616c10.1039/b717616c ↗
33. 10.1007/bf0281008110.1007/bf02810081 ↗
34. 10.1002/bies.95014110510.1002/bies.950141105 ↗
35. 10.1016/j.bbrc.2013.07.12510.1016/j.bbrc.2013.07.125 ↗
36. 10.1016/0014-4827(85)90173-910.1016/0014-4827(85)90173-9 ↗
37. 10.1039/c0sm00642d10.1039/c0sm00642d ↗
38. 10.1016/j.febslet.2010.10.04610.1016/j.febslet.2010.10.046 ↗
39. 10.1021/la202460510.1021/la2024605 ↗
40. 10.1152/ajpcell.1992.263.3.C55110.1152/ajpcell.1992.263.3.C551 ↗
41. 10.1016/s1357-2725(99)00005-910.1016/s1357-2725(99)00005-9 ↗
42. 10.1002/jbm.82026070410.1002/jbm.820260704 ↗
43. 10.1242/jcs.0007110.1242/jcs.00071 ↗
44. 10.3389/fcell.2016.0005310.3389/fcell.2016.00053 ↗
45. 10.1042/cs098029510.1042/cs0980295 ↗
46. 10.1152/ajprenal.00230.200210.1152/ajprenal.00230.2002 ↗
47. 10.1074/jbc.M110.12892610.1074/jbc.M110.128926 ↗
48. 10.1016/j.atherosclerosis.2016.01.03710.1016/j.atherosclerosis.2016.01.037 ↗
49. 10.1165/rcmb.2011-0187OC10.1165/rcmb.2011-0187OC ↗